



1653  
RECEIVED  
PATENT  
AUG 29 2001  
SAC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Nancy Malsich  
Nancy Malsich

8/23/01

Date of Deposit

Applicant: Lee, et al. )  
Serial No.: 09/581,044 ) Group Art Unit: 1653  
Filed: June 8, 2000 ) Examiner: J. Russel  
Title: HIV/FIV PROTEASE INHIBITORS ) Our Ref.: TSRI 609.1  
HAVING A SMALL P3 RESIDUE )

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT (37 CFR 1.121)

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Responsive to the Notice of Non-Compliant Amendment (Paper Number 9) mailed July 23, 2001, submitted herewith is the clean version of the replacement sequence paragraphs with instructions for entry and the marked-up version of the replacement paragraphs as amended on June 19, 2001.

At page 12, line 14, please substitute the following paragraph for the previous version:

1 Each compound tested in this study is a competitive inhibitor and is significantly more potent against HIV PR than FIV PR, as expected. However, the new inhibitors **1b-6b**, and **7a** showed a remarkable different pattern of inhibitory activities compared to their parent compounds **1a-5a**, ABT-538 and RO31-8959. Compounds **2a-4a**, containing no P3 moieties, exhibited marginal